jRCT2071230113进行中（未招募）不适用
A Phase 1,randomized,placebo-controlled,double-blind, single ascending dose and multiple ascending dose study of M132101 in healthy subjects.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 48
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 45age old not（—）
- 性别
- Male
入选标准
- •Males who are 18 to 44 years of age at the time of informed consent
排除标准
- •(1)Individuals with a history or complications with liver, kidney, or heart disease, etc. considered inappropriate for participation in the clinical study
- •(2)Individuals with abnormal findings (eczema/dermatitis, pigment abnormalities, inflammation due to sunburn, wounds, scars, skin infections, etc.) at the administration site.
- •(3)Individuals who are judged to be unsuitable as subject by the principal (sub) investigator
结局指标
主要结局
-
Tolerability, Safety, PK
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Single Ascending Dose and Multiple Ascending Dose Phase I study of PXS-4728A Administered Orally in Healthy Adult Males.Chronic Obstructive Pulmonary DiseaseRespiratory - Chronic obstructive pulmonary diseaseRespiratory - Other respiratory disorders / diseasesCystic FibrosisACTRN12614001326684Pharmaxis Ltd.72
已完成
1 期
A study of the safety and pharmacokinetics and pharmacodynamics of the LOXL2 inhibitor PXS-5338K in healthy male subjects given single and repeated doses.ACTRN12617001444370Pharmaxis Ltd72
已完成
1 期
First-in-Human Study of RLYB116 in Healthy Participantscomplement mediated diseasesBlood - Haematological diseasesInflammatory and Immune System - Autoimmune diseasesACTRN12621001571864IPC Research, LLC89
已完成
1 期
A Single Ascending Dose and Multiple Ascending Dose Phase 1 Study of PXS-5505A Administered Orally in Healthy Adult MalesACTRN12619000332123Pharmaxis Ltd56
已完成
1 期
A Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5382A Administered OrallyIdiopathic Pulmonary FibrosisACTRN12617001564347Pharmaxis72